Business context and reporting period
Ligand Pharmaceuticals Incorporated filed this unaudited Form 10-Q for the quarter ended March 31, 2015. Ligand’s business model centers on developing or acquiring royalty-generating assets and licensing products and technology to partners; it also sells Captisol material. The company reported two segments: Ligand and CyDex.
Financial performance and liquidity
Unless otherwise noted, amounts are in millions of dollars. Comparative figures are for the three months ended March 31, 2014.
| Metric | Q1 2015 | Q1 2014 |
|---|---|---|
| Revenue | $14.6 | $16.0 |
| Operating income | $3.3 | $5.1 |
| Operating margin | 22.9% | 32.0% |
| Net income attributable to Ligand | $0.8 | $2.1 |
| Diluted earnings per share | $0.04 | $0.10 |
| Cash from operating activities | $7.6 | $2.6 |
- Revenue comprised royalties of $10.3 million (up from $7.9 million), material sales of $3.7 million (down from $5.7 million), and collaborative R&D and other revenue of $0.6 million (down from $2.4 million). The consolidated statements show a net loss of $0.1 million including noncontrolling interests; the $0.8 million net income attributable to Ligand reflects $0.8 million of losses attributable to noncontrolling interests.
- Cash and cash equivalents were $165.8 million and short-term investments were $11.5 million at quarter-end. Working capital was $173.6 million. Cash and cash equivalents increased $5.6 million during the quarter.
- Convertible senior notes had $245.0 million principal outstanding and a $198.2 million net carrying value after unamortized discount. The notes bear 0.75% interest and mature in 2019. Net interest expense was $3.0 million, including noncash debt discount and issuance-cost amortization.
- Comprehensive income was $5.1 million, including a $4.6 million unrealized gain on available-for-sale securities.
Material changes versus the prior period
- Total revenue declined 8.5%. Higher royalties, primarily from Promacta and Kyprolis, were more than offset by lower Captisol material sales and fewer event-based payments.
- Operating income fell from $5.1 million to $3.3 million. R&D and general and administrative expenses each increased by about $0.9 million; lower material sales also reduced cost of sales by $1.4 million.
- Net income attributable to Ligand declined to $0.8 million from $2.1 million. Higher interest expense—following the 2014 convertible-note issuance—was a key factor.
- Operating cash flow increased to $7.6 million from $2.6 million, supported in part by a $5.2 million reduction in accounts receivable and noncash expenses. Investing activities used $2.8 million, principally for CVR and other contingency payments.
Outlook, commentary, risks and unusual items
- Management said existing cash, investments, and expected royalty, license, milestone, and Captisol revenues should fund operating and capital needs for at least the next 12 months. It expected cash to build, citing anticipated royalty growth, Captisol sales, approvals, licenses, and milestones. No specific financial guidance was provided.
- Key revenue risks include reliance on Promacta and Kyprolis royalties, Captisol sales, partner decisions and product performance, and a single Captisol supplier. The filing also notes customer concentration: three customers accounted for 77% of accounts receivable at quarter-end.
- In May 2015, Viking completed an IPO. Ligand purchased 1.1 million Viking shares for $9.0 million and received approximately 3.4 million shares under the amended license agreement, reaching approximately 49.8% ownership at IPO closing. Ligand expects an approximately $3.2 million cash payment to certain Metabasis CVR holders around January 1, 2016, subject to adjustment.
- Ligand’s contingent liabilities included approximately $9.4 million related to CyDex and $2.5 million related to Metabasis CVRs. Their fair values are sensitive to estimates and market prices. The company also remained legally liable to Organon for Avinza-related payments if Pfizer defaults, although the related recorded receivable and liability were each $0.1 million at quarter-end.
- A securities lawsuit naming Ligand and its CEO was pending; Ligand had moved to dismiss, and the outcome was described as not presently determinable. Management reported disclosure controls were effective and no material change in internal control over financial reporting during the quarter.
- Other notable items: Ligand acquired additional Selexis program financial rights for $4.0 million in May 2015. The company had no off-balance-sheet arrangements and made no share repurchases in the quarter.
Important facts for investors to verify
- Whether Promacta and Kyprolis royalties and Captisol demand continue to offset variability in material sales and milestone revenue.
- The terms, accounting and potential realizable value of Ligand’s Viking ownership, amended royalty rights, loan, and expected CVR payment.
- The 2019 notes’ cash repayment, conversion and dilution exposure, including the effect of the bond hedges and warrants.
- Captisol supply continuity and customer concentration, and the assumptions underlying CyDex and other contingent liabilities.
- Developments in the securities litigation and whether the company achieves the cash-flow and 12-month liquidity outlook described by management.